Perfume Packaging

Description

THIS INDUSTRIAL MODEL REFERS TO A NEW ORIGINAL DESIGN FOR A PACKAGE PERFUME, CHARACTERIZED BY BEING COMPOSED OF THE BODY OF THE CONTAINER AND A CAP. THE BODY OF THE CONTAINER HAS THE FOLLOWING SPECIAL CHARACTERISTICS: - IT IS OVAL. - IT HAS CONVEX LATERAL CONTOURS. - IT HAS CONVEX FRONT AND POSTERIOR CONTOURS. - IT HAS A COLINDRICAL NECK AND AN ANNULAR BAND. THE LID HAS THE FOLLOWING SPECIAL FEATURES: - IT IS OVAL. - IT HAS A ROUNDED FRONT CONTOUR - IT HAS A ROUNDED CONVEX SURFACE. 43 4949-4957, XP055060298, ISSN: 0022-2623, DOI: 10.1021 / JM1003792 COMPOUND 4B Claims affected 1-6,11,12,15 X MICHAEL J. SOFIA ET AL: «DISCOVERY OF A BETA-D-2' -DEOXY-2 -ALPHA-FLUORO-2'-BETA￾C-METHYLURIDINE NUCLEOTIDE PRODRUG (PSI-7977) FOR THE TREATMENT OF HEPATITIS C VIRUS», JOURNAL OF MEDICINAL CHEMISTRY, VOL. 53, N° 19, 16 SEPTEMBER 2010 (2010-09-16), PAGES 7202- 7218, XP055004442, ISSN: 0022-2623, DOI: 10.1021 / JM100863X COMPOUND 40 Reivindicaciones afectadas 1-6,8,10,12,15 X CHRISTOPHER MCGUIGAN ET AL: «PHOSPHORODIAMIDATES AS A PROMISING NEW PHOSPHATE PRODRUG MOTIF FOR ANTIVIRAL DRUG DISCOVERY: APPLICATION TO ANTI-HCV AGENTS»; JOURNAL OF MEDICINAL CHEMISTRY, VOL. 54, N° 24, 22 DECEMBER 2011 (2011-12-22), PAGES 8632-8645, XP055058426, ISSN: 0022-2623, DOI: 10.1021 / JM2011673 PAGE 29 Reivindicaciones afectadas 1- 6,8,11,12,15 X COSTANTINO CONGIATU ET AL: «NOVEL POTENTIAL ANTICANCER NAPHTHYL PHOSPHORAMIDATES OF BVDU: SEPARATION OF DIASTEREOISOMERS AND ASSIGNMENT OF THE ABSOLUTE CONFIGURATION OF THE PHOSPHORUS CENTER», JOURNAL OF MEDICINAL CHEMISTRY, VOL. 49, N° 2, 1 JANUARY 2006 (2006-01- 01), PAGES 452-455, XP055068007, ISSN: 0022-2623, DOI: 10.1021 / JM0509896 COMPOUND 10 Reivindicaciones afectadas 1-6,8,12 X MEHELLOU, YOUCEF ET AL: «THE DESIGN, SYNTHESIS AND ANTIVIRAL EVALUATION OF A SERIES OF 5-TRIMETHYLSILYL-1-.BETA.-D-(ARABINOFURANOSYL)URACIL PHOSPHORAMIDATE PROTIDES», ANTIVIRAL CHEMISTRY & CHEMOTHERAPY, 20(4), 153-160 CODEN: ACCHEH; ISSN: 0956-3202 URL: HTTP: / / WWW.INTMEDPRESS.COM / JOURNALS / AVCC / A BSTRACT.CFM?ID=1476&PID=108, 2010, XP002700109, DOI: 10.3851 / IMP1476 COMPOUND 10 Reivindicaciones afectadas 1-6,8,12 P,X WO 2013 / 039855 A1 (IDENIX PHARMACEUTICALS INC [US]; SURLERAUX DOMINIQUE [BE]; DOUSSON CYR) 21 MARCH 2013 (2013-03-21) THE WHOLE DOCUMENT Reviews affected 1-15 P,X WO 2012 / 154321 A1 (IDENIX PHARMACEUTICALS INC [US]; CENTER NAT RECH SCIENT [FR]; SURLERAU) 15 NOVEMBER 2012 (2012-11-15) THE WHOLE DOCUMENT Reviews affected 1-15 X WO 2012 / 040126 A1 (ALIOS BIOPHARMA INC [US]; BEIGELMAN LEONID [US]; BLATT LAWRENCE [US];) 29 MARCH 2012 (2012-03-29) PAGE 222 RIGHT HAND COL. LAST CMPD PAGE 225 RIGHT HAND COL. 4TH / 5TH ROWS PAGE 226 RIGHT HAND COL. 1ST ROW PAGE 227 RIGHT HAND COL. 1ST ROW Returns affected 1-4,6,8,11,12,15 P,X WO 2012 / 142075 A1 (MERCK SHARP & DOHME [US]; GIRIJAVALLABHAN VINAY [US]; NJOROGE F GEORGE) 18 OCTOBER 2012 (2012-10-18) THE WHOLE DOCUMENT Reviews affected 1-15 X WO 2011 / 039221 A2 (CENTOCOR ORTHO BIOTECH PRODUCTS LP [US]; MEDIVIR AB [SE]; JONCKERS TI) 7 APRIL 2011 (2011-04-07) COMPOUNDS 1-35 Reivindicaciones afectadas 1-5,8,12,15 X WO 2010 / 135520 A1 (CHIMERIX INC [US]; ALMOND MERRICK [US]; LANIER ERNEST RANDALL [US]; MU) 25 NOVEMBER 2010 (2010-11-25) PAGE 87; COMPOUND 17 PAGE 89; COMPOUND 18 PAGE 91; COMPOUND 22 PAGE 93; COMPOUND 23 Reivindicaciones afectadas 1-6,8,12